应对缺乏证据:在SARS-CoV-2大流行的初始阶段活体供体肾移植。

IF 0.6 4区 医学 Q4 SURGERY
Nadina Roth, Christiane Sophie Rösch, Axel Krause, Manfred Kalteis, Wolfgang Enkner, Maria Haller, Daniel Cejka, Reinhold Függer, Matthias Biebl
{"title":"应对缺乏证据:在SARS-CoV-2大流行的初始阶段活体供体肾移植。","authors":"Nadina Roth,&nbsp;Christiane Sophie Rösch,&nbsp;Axel Krause,&nbsp;Manfred Kalteis,&nbsp;Wolfgang Enkner,&nbsp;Maria Haller,&nbsp;Daniel Cejka,&nbsp;Reinhold Függer,&nbsp;Matthias Biebl","doi":"10.1007/s10353-022-00781-9","DOIUrl":null,"url":null,"abstract":"<p><p>Due to immunosuppressive therapy, transplant patients are more susceptible to viral and bacterial infections. A potentially deadly new virus haunted us in 2020: SARS-CoV‑2, causing coronavirus disease 19 (COVID-19). We analyzed the consequences of this previously unknown risk for our living-donor transplant program in the first year of the pandemic. After the complete lockdown in spring 2020, our transplant center in Linz resumed the living-donor kidney transplantation program from June to September 2020, between the first and second waves of COVID-19 in Austria. We compared the outcomes of these living-donor kidney transplantations with the transplant outcomes of the corresponding periods of the three previous years. From June 4 to September 9, 2020, five living-donor kidney transplantations were performed. All donors and recipients were screened for COVID 19 infection by PCR testing the day before surgery. Kidney transplant recipients remained isolated in single rooms until discharge from hospital. All recipients and donors remained SARS-CoV‑2 negative during the follow-up of 10 months and have been fully vaccinated to date. The number of living transplants in the studied period of 2020 was constant compared to the same months of 2017, 2018, and 2019. Living-donor kidney transplantation can be continued using testing for SARS-CoV‑2 and meticulous hygienic precautions in epidemiologically favorable phases of the SARS-CoV‑2 pandemic. Donors and recipients should be carefully selected and informed about risks and benefits.</p>","PeriodicalId":50475,"journal":{"name":"European Surgery-Acta Chirurgica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562069/pdf/","citationCount":"0","resultStr":"{\"title\":\"Coping with a lack of evidence: living-donor kidney transplantation in the initial phase of the SARS-CoV-2 pandemic.\",\"authors\":\"Nadina Roth,&nbsp;Christiane Sophie Rösch,&nbsp;Axel Krause,&nbsp;Manfred Kalteis,&nbsp;Wolfgang Enkner,&nbsp;Maria Haller,&nbsp;Daniel Cejka,&nbsp;Reinhold Függer,&nbsp;Matthias Biebl\",\"doi\":\"10.1007/s10353-022-00781-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Due to immunosuppressive therapy, transplant patients are more susceptible to viral and bacterial infections. A potentially deadly new virus haunted us in 2020: SARS-CoV‑2, causing coronavirus disease 19 (COVID-19). We analyzed the consequences of this previously unknown risk for our living-donor transplant program in the first year of the pandemic. After the complete lockdown in spring 2020, our transplant center in Linz resumed the living-donor kidney transplantation program from June to September 2020, between the first and second waves of COVID-19 in Austria. We compared the outcomes of these living-donor kidney transplantations with the transplant outcomes of the corresponding periods of the three previous years. From June 4 to September 9, 2020, five living-donor kidney transplantations were performed. All donors and recipients were screened for COVID 19 infection by PCR testing the day before surgery. Kidney transplant recipients remained isolated in single rooms until discharge from hospital. All recipients and donors remained SARS-CoV‑2 negative during the follow-up of 10 months and have been fully vaccinated to date. The number of living transplants in the studied period of 2020 was constant compared to the same months of 2017, 2018, and 2019. Living-donor kidney transplantation can be continued using testing for SARS-CoV‑2 and meticulous hygienic precautions in epidemiologically favorable phases of the SARS-CoV‑2 pandemic. Donors and recipients should be carefully selected and informed about risks and benefits.</p>\",\"PeriodicalId\":50475,\"journal\":{\"name\":\"European Surgery-Acta Chirurgica Austriaca\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562069/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Surgery-Acta Chirurgica Austriaca\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10353-022-00781-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Surgery-Acta Chirurgica Austriaca","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10353-022-00781-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

由于免疫抑制治疗,移植患者更容易受到病毒和细菌感染。2020年,一种可能致命的新病毒困扰着我们:SARS-CoV - 2,它导致了冠状病毒病19 (COVID-19)。在流感大流行的第一年,我们分析了这种以前未知的风险对活体供体移植计划的影响。在2020年春季全面封锁后,我们在林茨的移植中心于2020年6月至9月恢复了活体供体肾移植项目,这段时间正值奥地利第一波和第二波新冠肺炎疫情期间。我们将这些活体肾移植的结果与前三年相应时期的移植结果进行了比较。2020年6月4日至9月9日,共施行活体肾移植5例。手术前一天,所有供体和受体均通过PCR检测筛查COVID - 19感染。肾移植受者在出院前一直被隔离在单间。在10个月的随访期间,所有受赠者和捐赠者均为SARS-CoV - 2阴性,并且迄今已完全接种了疫苗。与2017年、2018年和2019年同期相比,2020年研究期间的活体移植数量保持不变。在SARS-CoV - 2大流行的有利流行病学阶段,可以通过SARS-CoV - 2检测和细致的卫生预防措施继续进行活体供体肾移植。应仔细选择捐助者和受援者,并告知其风险和利益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Coping with a lack of evidence: living-donor kidney transplantation in the initial phase of the SARS-CoV-2 pandemic.

Due to immunosuppressive therapy, transplant patients are more susceptible to viral and bacterial infections. A potentially deadly new virus haunted us in 2020: SARS-CoV‑2, causing coronavirus disease 19 (COVID-19). We analyzed the consequences of this previously unknown risk for our living-donor transplant program in the first year of the pandemic. After the complete lockdown in spring 2020, our transplant center in Linz resumed the living-donor kidney transplantation program from June to September 2020, between the first and second waves of COVID-19 in Austria. We compared the outcomes of these living-donor kidney transplantations with the transplant outcomes of the corresponding periods of the three previous years. From June 4 to September 9, 2020, five living-donor kidney transplantations were performed. All donors and recipients were screened for COVID 19 infection by PCR testing the day before surgery. Kidney transplant recipients remained isolated in single rooms until discharge from hospital. All recipients and donors remained SARS-CoV‑2 negative during the follow-up of 10 months and have been fully vaccinated to date. The number of living transplants in the studied period of 2020 was constant compared to the same months of 2017, 2018, and 2019. Living-donor kidney transplantation can be continued using testing for SARS-CoV‑2 and meticulous hygienic precautions in epidemiologically favorable phases of the SARS-CoV‑2 pandemic. Donors and recipients should be carefully selected and informed about risks and benefits.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
36
审稿时长
6-12 weeks
期刊介绍: The journal European Surgery – Acta Chirurgica Austriaca focuses on general surgery, endocrine surgery, thoracic surgery, heart and vascular surgery. Special features include new surgical and endoscopic techniques such as minimally invasive surgery, robot surgery, and advances in surgery-related biotechnology and surgical oncology. The journal especially addresses benign and malignant esophageal diseases, i.e. achalasia, gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma. In keeping with modern healthcare requirements, the journal’s scope includes inter- and multidisciplinary disease management (diagnosis, therapy and surveillance).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信